News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Amgen Drug AMG-102 Has Little Impact On Brain Cancer
May 16, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LOS ANGELES, May 15 (Reuters) - Amgen Inc's (AMGN.O: Quote, Profile, Research) experimental drug AMG-102 may be effective in only a subpopulation of patients with recurring brain tumors, according to results from a small mid-stage trial.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
MORE ON THIS TOPIC
Huntington’s disease
FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy
December 4, 2025
·
2 min read
·
Heather McKenzie
FDA
New Approach Methodologies: Redefining Animal Testing Alternatives
December 4, 2025
·
1 min read
·
BioSpace Insights
Policy
New UK/EU Rules and AI Adoption Define CRO Priorities for 2026
December 3, 2025
·
4 min read
·
Jennifer Smith-Parker
Duchenne muscular dystrophy
Capricor Heads Back to FDA With Pivotal Results for DMD Cardiomyopathy Therapy
December 3, 2025
·
3 min read
·
Heather McKenzie
